Japan· JP-1124015M2038
クロラゼプ酸二カリウム
A potassium clorazepate product containing クロラゼプ酸二カリウム, registered in Japan by ヴィアトリス製薬, on the national reimbursement list. The same ATC class is registered in 7 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Potassium clorazepate is registered in 7 of 19 countries.
Countries holding a registration under ATC N05BA05 (potassium clorazepate), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 4 of them publish a price we can compare per daily dose
Potassium clorazepate · ATC N05BA05
7 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of potassium clorazepate costs, country by country.
Normalised to the WHO defined daily dose (20 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Potassium clorazepate · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.83
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- クロラゼプ酸二カリウム
- Manufacturer
- ヴィアトリス製薬
- Country
- Japan (JP)
- ATC code
- N05BA05
- ATC class
- Potassium clorazepate
- Defined daily dose
- 20 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
192 interactions on record for potassium clorazepate.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Potassium clorazepate · interactions on record
192 records
- 4 severe
- 117 moderate
- 22 minor
Most severe, free to view
- MorphineN02AA01severe
- MorphinN07BC09severe
- HydrocodoneR05DA03severe
- CodeineR05DA04severe
49 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Potassium clorazepate in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1ca15a3e-b05a-4d5c-af43-de8eee7d0f81 GET /v1/drugs/1ca15a3e-b05a-4d5c-af43-de8eee7d0f81?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "７．５ｍｇ１カプセル",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "1124015M2038",
"category": "内用薬",
"price_yen": 10.8,
"generic_name": "クロラゼプ酸二カリウム",
"product_name_jp": null,
"therapeutic_class": "1124",
"transitional_expiry": null
}See everything about potassium clorazepate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.